-
Mashup Score: 0Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML - 9 hour(s) ago
PURPOSE Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, FLT3 mutations are a common mechanism of resistance to this regimen. The addition of gilteritinib, an oral FLT3 inhibitor, to azacitidine and venetoclax may improve outcomes in patients with FLT3-mutated AML. METHODS This phase I/II study evaluated azacitidine, venetoclax, and gilteritinib in two cohorts: patients with (1) newly diagnosed FLT3-mutated AML who were unfit for intensive chemotherapy or (2) relapsed/refractory FLT3-mutated AML (ClinicalTrials.gov identifier: NCT04140487). The primary end points were the maximum tolerated dose of gilteritinib (phase I) and the combined complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate (phase II). RESULTS Fifty-two patients were enrolled (frontline [n = 30]; relapsed/refractory [n = 22]). The recommended phase II dose was gilteritinib 80 mg once daily in combination with a
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q) - 18 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0What Conditions Account for US Health Spending? - 25 day(s) ago
The Bureau of Economic Analysis releases interesting data on health spending by condition.
Source: healthy-skeptic.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 43A spatiotemporal proteomic map of human adipogenesis - 28 day(s) ago
Nature Metabolism – Klingelhuber, Frendo-Cumbo et al. develop a proteomic atlas elucidating the intracellular spatiotemporal changes in protein levels and localizations during human adipogenesis.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0R.I.P. Louis Gossett Jr.: First Black actor to win Oscar for Best... - 1 month(s) ago
The award was for his role in the 1982 romantic drama An Officer and a Gentleman.
Source: decider.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15 Things To Know About Colon Cancer Prevention and Screening - 1 month(s) ago
Colorectal cancer is the third most common cancer in the United States, and more than 150,000 people will be diagnosed with colorectal cancer this year. For
Source: medicine.yale.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Joe Lieberman, 2000 vice presidential nominee, dies at 82 - 1 month(s) ago
He was the first Jewish American to be nominated on a major party’s ticket.
Source: www.politico.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0stats - 1 month(s) ago
National Center for Health Statistics
Source: www.cdc.govCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 17A unique chaperoning mechanism in class A JDPs recognizes and stabilizes mutant p53 - 1 month(s) ago
Zoltsman et al. discovered a unique chaperoning mechanism present in class A JDPs that protects destabilized β sheet-rich proteins from misfolding and aggregation. A β-hairpin site in these chaperones senses the increase in protein dynamics upon client misfolding. However, this same chaperone mechanism likewise protects oncogenic mutant p53, thus promoting cancer progression.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Plasma membrane damage is a new trigger of cellular senescence - 1 month(s) ago
By blocking proliferation and inducing a secretory phenotype, cellular senescence has beneficial and deleterious effects, the latter being linked to aging. Suda et al. recently reported that plasma membrane (PM) damage (PMD) triggers senescence, suggesting that PMD inducers promote senescence and that the PMD repair machinery can regulate it.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
https://t.co/aPwYnYvI6d